Vivos, Inc. Completes Common Stock Equity Financing to Fund Roll Out of IsoPet™ and Eliminate Toxic Debt
10 oct. 2018 07h00 HE
|
Vivos Inc.
Richland WA, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Vivos, Inc. (OTC PINK: RDGL) Vivos, Inc. a pharmaceutical company researching and developing minimally invasive treatments to combat cancer in humans...
Vivos Inc Signs Memorandum of Understanding with Private Veterinary Hospital as Pilot Clinic for Commercial IsoPet® Therapy
02 oct. 2018 07h00 HE
|
Vivos Inc.
Richland, WA, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) selected its first clinic for commercial sales of IsoPet Vivos Inc., a pharmaceutical company in the process of researching and...
Vivos Inc Successfully Treats Canine Sarcoma with IsoPet™ (RadioGel™)
31 mai 2018 06h00 HE
|
Vivos Inc.
Richland, WA, May 31, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) successfully treated canine soft tissue sarcoma with its proprietary IsoPet™ (RadioGel™), a hydrogel liquid containing tiny...
Vivos Demonstrates that IsoPet™ (RadioGel™) is effective in killing cancer in cats
01 mai 2018 09h00 HE
|
Vivos Inc.
Richland, WA, May 01, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) announced today the results from the therapy for feline sarcoma. Five cats were treated at Washington...
Vivos Adds Commercial Expertise to its Veterinary Medicine Advisory Board
20 mars 2018 09h30 HE
|
Vivos Inc.
Richland, WA, March 20, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) announced today that it added a new member on the Veterinary Medicine Advisory Board. Tariq Shah BSc. DipMS is the...
Vivos Receives FDA Confirmation of RadioGel Device Classification for Animal Skin Cancer Therapy
30 janv. 2018 09h00 HE
|
Vivos Inc.
Richland, WA, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) announced today that it has been notified by the FDA that RadioGel™ is classified as a device for animal therapy. ...
Vivos Completes Planned Dosing Schedule for Feline Sarcoma Program
12 janv. 2018 11h54 HE
|
Vivos Inc.
Richland, WA, Jan. 12, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) announced today that it has completed its planned dosing schedule to determine the effectiveness of using the Company’s...